Esperion Stock Surges On ARCHIMED’s $1.1 Billion Buyout — What Shareholders Get Next
ARCHIMED will acquire Esperion Therapeutics for $3.16 per share in cash plus a contingent value right tied to future sales, valuing the deal at up to $1.1 billion. Esperion shares surged 56% to near the cash offer after the announcement. The CVR could pay up to $100 million if sales targets are met. The deal follows Esperion’s recent expansion beyond cholesterol drugs.